Mylan failed to meet the burden to trigger review of a patent covering Bayer’s drug Xarelto, the Patent Trial and Appeal Board said in a decision on its electronic docket. The board Dec. 3 declined to institute review of the patent, U.S. Patent No. 9,539,218, for a way of treating blood-clot disorder with a once-daily dose of the drug. Mylan claimed the patent didn’t cover a new invention, and filed a petition for review after Bayer and partner Johnson & Johnson sued to prevent Mylan from selling a generic version of the drug. The patent expires in February 2034, according... To read the full article . To learn more about a subscription .
The US Patent Trial and Appeal Board has ruled against Roche in its attempts to force a patent trial of Bayer 's blood clot disorder patent . It had argued that the patent did not concern a new drug and had launched the trial after it was prevented from developing a generic version by a joint patent and J&J suit .